Benign Prostatic Hyperplasia News and Research

RSS

NeoTract selects SYSPRO ERP

SYSPRO, the leading provider of visionary, pragmatic ERP software, today announced that NeoTract, Inc., a Medical Device start-up company headquartered in Pleasanton, Calif., has selected SYSPRO ERP (Enterprise Resource Planning) software to manage the company's financial, manufacturing and distribution operations.

29 Jul 2010

Nymox provides update on NX-1207 Phase 3 program for benign prostatic hyperplasia

Nymox Pharmaceutical Corporation provided an update today on the Company's Phase 3 program for NX-1207, Nymox's investigational drug for benign prostatic hyperplasia (BPH). The Safety Monitoring Committee meeting of July 22, 2010 for the Phase 3 U.S. pivotal trials of NX-1207 was favorable and indicated no significant safety concerns for the trials to date. Patient recruitment and trial activities for pivotal U.S. studies NX02-0017 and NX02-0018 are proceeding at over 70 well-known urology investigative sites throughout the U.S.

29 Jul 2010

Aphios awarded US patent for compositions, methods for treating diseases involving 5-α reductase enzyme

Aphios® Corporation today announced that it was awarded United States Patent No. 7,744,935 B2 for "Compositions and Methods for Inhibiting 5-α Reductase," granted June 29, 2010. This invention is related to compositions and methods for treating diseases involving the 5-alpha (α) reductase enzyme.

28 Jul 2010

DermaGenoma announces availability of PsoriasisDX Genetic Test as CE Marked product for PsA

Molecular dermatology research and development innovator DermaGenoma, Inc. today announced that the PsoriasisDX Genetic Test for Psoriatic Arthritis is now available as a CE Marked product under the European In Vitro Diagnostic Directive.

21 Jul 2010

ARUP enters partnership to offer deCODE's DNA-based prostate cancer risk assessment test

deCODE genetics and ARUP Laboratories today announced a partnership through which ARUP will offer deCODE's DNA-based prostate cancer risk assessment test to its clients nationwide.

20 Jul 2010

USFDA approves Sun Pharma's generic Flomax ANDA

Sun Pharmaceutical Industries Ltd. announced that USFDA has granted approval for its Abbreviated New Drug Application to market a generic version of Flomax ®, tamsulosin capsules.

16 Jul 2010

Study links high-fat diet as potential cause of prostatic diseases

Prostate cancer is the second leading cause of cancer-related deaths in men with an estimated 192,280 new cases diagnosed in the US in 2009 (Jemal 2009). Diet is considered one of the most important controllable risk factors for inflammation and prostate diseases including benign prostatic hyperplsia, prostatitis, and prostate cancer.

15 Jul 2010

SPET-085 is effective in blocking critical enzyme that leads to BPH: Study

A new study, published in the July issue of Advances in Therapy, revealed that a novel saw palmetto extract, SPET-085, is as effective as finasteride, the standard prescription drug therapy, in blocking the critical enzyme that leads to benign prostatic hyperplasia.

13 Jul 2010

Nymox near completion of new NX-1207 follow-up study for BPH

Nymox Pharmaceutical Corporation announced today that the Company is nearing completion of a new multi-center U.S. long-term follow-up study of NX-1207, its investigational drug for the treatment of benign prostatic hyperplasia (BPH). Nymox expects to report final results and statistical analysis for the study in the next 1-2 weeks. The new study concerns assessment of the 48-60 month efficacy and benefits of a single treatment of NX-1207.

16 Jun 2010

DermaGenoma releases CelluliteDX Genetic Test for women

As summer swimsuit season heats up, women around the world will inspect their looks in the mirror. A majority of them will see cellulite - at some point - but a new genetic test may be able to help them avoid cellulite before anyone notices.

10 Jun 2010

Ongoing clinical development program for NX-1207 for treatment of BPH highlighted

Nymox Pharmaceutical Corporation is pleased to report on the presentation of new positive data at a high-level symposium and panel discussion held at the Annual Meeting of the American Urological Association in San Francisco. The symposium was held between 6:00 and 7:00 pm EDT on Tuesday. The well-attended symposium highlighted the ongoing clinical development program for NX-1207 for the treatment of benign prostatic hyperplasia and featured expert panel discussions on the new therapy.

4 Jun 2010

Protox Therapeutics reports positive data from Phase 2b study of PRX302 in BPH

Protox Therapeutics Inc., a leader in the development of receptor targeted fusion proteins, today announced positive six month data from its double-blind placebo controlled Phase 2b study of PRX302 (study name: TRIUMPH) in patients with moderate to severe benign prostatic hyperplasia (BPH) a bothersome urologic condition that affects the quality of life of more than 50 million men worldwide.

2 Jun 2010

Protox announces presentations on PRX302 for BPH at 2010 AUA Annual Meeting

Protox Therapeutics Inc., a leader in the development of receptor targeted fusion proteins, today announced that two oral podium presentations on the company's lead candidate, PRX302, will be made at the 2010 Annual Meeting of the American Urological Association (AUA). These presentations will include six month data from the Phase 2b clinical study of PRX302 called TRIUMPH, in patients with moderate to severe benign prostatic hyperplasia (BPH).

1 Jun 2010

Surgery more beneficial than drug therapy for benign prostatic hyperplasia

A 17-year-long community study looking at symptoms of enlarged prostate in over 2,000 men age 40 to 79 years suggests that surgery for benign prostatic hyperplasia (BPH) offers more relief from incontinence and obstruction symptoms than treatment from drug-based therapy, according to a new study by researchers at Mayo Clinic.

31 May 2010

Clinical abstracts on Urologix' Cooled ThermoTherapy selected for presentation at AUA's GUS meeting

Urologix®, Inc., a medical device company that develops, manufactures and markets minimally invasive Cooled ThermoTherapy™ technology to urologists to provide a durable and effective in-office treatment for patients suffering from benign prostatic hyperplasia (BPH), announced the selection of two clinical abstracts for podium presentation at the American Urological Association (AUA) 2010 Annual Meeting's sub-specialty society, the Geriatric Urological Society (GUS) meeting.

29 May 2010

New GreenLight XPS Laser System launched for treatment of BPH

American Medical Systems, a leading provider of world-class devices and therapies for both male and female pelvic health, today announced the launch and immediate availability of its new GreenLight XPS (Xcelerated Performance System) for laser treatment of benign prostatic hyperplasia or enlarged prostate.

29 May 2010

Nymox Pharmaceutical announces symposium and panel discussion on NX-1207 drug for BPH

Nymox Pharmaceutical Corporation is pleased to announce the presenters and participants for the symposium and panel discussion on NX-1207, the Company's Phase 3 drug for benign prostatic hyperplasia (BPH), to be held during the 2010 Annual Meeting of the American Urological Association in San Francisco at 3:00 p.m. June 1.

28 May 2010

New multi-center follow-up study of NX-1207 for treatment of BPH to be completed

19 May 2010

Protox announces positive top-line results from the TRIUMPH study in first quarter 2010

Protox Therapeutics Inc. a leader in the development of receptor targeted fusion proteins, today released financial results for the first quarter 2010, ended March 31, 2010. "The first quarter of 2010 marked significant achievements for the company, namely the announcement of positive top-line results from the TRIUMPH study and the subsequent completion of a five million dollar financing," said Dr. Fahar Merchant, President and CEO of Protox.

15 May 2010

Nymox attributes increase in first-quarter net losses to higher clinical trial expenditures

Nymox Pharmaceutical Corporation announced today its financial results for the first quarter of 2010. Nymox reported a net loss of $1,269,550, or $0.04 per share for the quarter ending March 31, 2010, compared to $1,004,259, or $0.03 per share for same period in 2009. Net losses include stock compensation charges of $195,220 in 2010 and $309,650 in 2009.

14 May 2010